| Second-Line Drug for Advanced RCC Improves PFS - Renal and Urology News |
|
|
Renal and Urology News CHICAGO—An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma (mRCC), according to data presented at the 47th Annual |